Theravance Biopharma (TBPH) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

TBPH Theravance Biopharma

Watchlist

9.840
+0.400+4.24%

Close Dec 3 16:00 ET

9.840
0.0000.00%

Post 16:02 ET

483.88MMarket Cap-9553P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Theravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireNov 20 06:00 ET
A Quick Look at Today's Ratings for Theravance Biopharma(TBPH.US), With a Forecast Between $9 to $15
Moomoo NewsNov 14 08:00 ET · Ratings
Theravance Biopharma | 10-Q: Q3 2024 Earnings Report
SECNov 14 06:11 ET · Announcements
Baupost's Top Q3 Trades Include Jazz Exit, New Dollar General Stake
Seeking AlphaNov 13 17:36 ET
Theravance Biopharma Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Sales Results.
BenzingaNov 13 12:55 ET
Express News | Theravance Biopharma Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Sales Results
BenzingaNov 13 12:55 ET

Comments

Moomoo AI

Feb 5 08:17

Analysts show high confidence in Theravance Biopharma's growth rate, predicting a breakeven point by 2026. The company's lack of debt, which is unusual for a loss-making pharma, reduces the risk around investing in the company.

Theravance Biopharma, Inc.'s (NASDAQ:TBPH) Shift From Loss To Profit

Moomoo AI

Jan 9 06:20

Theravance Biopharma's high P/S ratio is alarming considering its unimpressive revenue predictions. Investors seem hopeful for a business turnaround, but analysts lack confidence. The anticipated revenue growth could pressure the share price.

Investor Optimism Abounds Theravance Biopharma, Inc. (NASDAQ:TBPH) But Growth Is Lacking

Moomoo AI

Dec 21, 2023 18:34

The appointment of Jeremy Grant and the cooperation with Irenic are seen as positive steps towards strengthening Theravance's position. Irenic supports Theravance's potential to successfully complete the Phase 3 trial of ampreloxetine and deliver enhanced value to shareholders.

Press Release: Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Trytosaveabit

Nov 13, 2023 07:25

Update

$Theravance Biopharma (TBPH.US)$ Viatris And Theravance Biopharma Announce Top-Line Results From Yupelri Phase III Trial In China For The Treatment Of Chronic Obstructive Pulmonary Disease
Moomoo 24/7· 3 mins ago

Moomoo AI

Nov 12, 2023 06:46

The consensus remains at US$14.50 despite weaker earnings forecast, suggesting a belief in a minimal long-term impact to valuation. Yet, the rise in anticipated losses next year and reduced revenue predictions might raise investor concerns about Theravance Biopharma.

Bearish: Analysts Just Cut Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenue and EPS Estimates

Heat List

Overall

No Data